October 2021
`
`CURRICULUM VITAE
`
`Faculty of Medicine
`Department of Medicine
`
`
`
`JOHN C. BELL, PhD
`
`
`DEGREES:
`
` Hons. B.Sc.
` Ph.D.
`
`
`
`
`McMaster University Biology June 1977
`McMaster University Virology and Immunology June 1983
`
`
`EMPLOYMENT HISTORY
`
`
`AWARDS
`
`
` Scientific Director, Networks of Centres of Excellence, BioCanRx.
`2014-present
` Director of the Ontario Institute for Cancer Research Bio-therapeutics Program 2007-2019
` Senior Scientist, Ottawa Hospital Research Institute
`2005-present
` Co-Founder and Chief Scientific Officer Jennerex Biotherapeutics
`2006-2013
` Co-Founder of Turnstone Biologics
`2016-present
` Professor, University of Ottawa, Department of Medicine
`1999-present
` Associate Professor, University of Ottawa Department of Medicine
`1989-1999
` Assistant Professor, McGill University, Department of Biochemistry
`1986-1989
` Post-Doctoral Fellow, National Institute for Medical Research, London, UK.
`1985-1986
` Post-Doctoral Fellow, University of Ottawa
`1982-1985
`
`
`
` FRSQ Chercheur-Bousier
`1987
` MRC Scholarship
`1988
` MRC Scientist Award
`1993
` NCI Senior Scientist
`1993
` OHRI Researcher of the Year
`2000
` David Grimes Award
`2010
` Robert L. Noble Outstanding Achievement Cancer Research
`2011
` McMaster University Distinguished Alumni Award
`2012
` Queen’s Diamond Jubilee Award
`2012
` Order of the City of Ottawa
`2012
` The Royal Society of Canada
`2013
` European Society for Gene and Cell Therapy Public and Patient Engagement Award. 2019
` CSCI Distinguished Scientist Award and Lecture
`2020
` Dr. Chew Wei Memorial Prize in Cancer Research
`2021
`
`Page 1 of 13
`
`TRANSGENE/BIOINVENT
`EXHIBIT 1006
`
`

`

`
`Grant Panel Memberships and Advisory Boards
`
` 2005-2010 NCIC Clinical Trials Executive Committee
`
` 2007-2010 Member of the Medical Review Panel for The Gairdner Foundation
` 2006-2014 Scientific Advisory Board, Jennerex Inc.
` 2007-2014 Panel Member for European Commission for Medical & Public Health Research
` 2013-2014 Cancer Gene Therapy Editorial Board
` 2013-2014 Panel Member CCSRI Innovation Grants
` 2003-2021 Organizing committee for the international Meeting on Oncolytic
` Virus Therapeutics
` 2004-2021 Editorial board for Molecular Therapy
` 2013-2020 Co-Chair Alberta Cancer Foundation Grants Panel
` 2013-2019 Terry Fox Program Project Grant Panel
` 2013-2018 CIHR Industrial Partnership Panel
` 2014-2018 Chair CCSRI Impact Grants Panel
` 2015-2020 Board Member Turnstone Biologics
` 2018-2021 Scientific Advisory Board for the Human Health Therapeutics Program
` 2017-2021 Scientific Advisory Board for the McGill Cancer Centre
` 2019
`Co-Chair of Canadian Cancer Research Conference
` 2019-2021 Chair for the Cancer Biology and Therapeutics Panel – CIHR
` 2019-2021 Scientific Advisory Board for the TFRI Montreal Cancer Consortium
` 2019-2021 Editorial Board Journal of Immunotherapy for Cancer
`
`2020 - 2023
`
`2020-2022
`
`June 1, 2020-
`May 31, 2021
`
`
`Amount
`$857,700
`
`$199,958
`
`$200,000
`
`$1,936,150
`
`
`GRADUATE SUPERVISION
`
` Career Number: 24 PhD,
` Completed:
`22 PhD,
`
`In Progress:
` 2 PhD,
`
`ONGOING EXTERNAL RESEARCH FUNDING
`
`
`Year
`Source
`2020-2024
`BioCanRx. Viral Ventures Legacy Activity 01-
`Therapeutic Virus Manufacturing Core
`
`BioCanRx. Development of a Virally Programmed
`Exosome-based Cancer Vaccine Platform
`
`Canadian Cancer Society “Oncolytic virus therapy
`for U1-mutant cancers”.
`
`Canadian Institutes of Health Research,
`Development of Vaccines to Prevent SARS-CoV-2
`Infection in High Risk Individuals
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`34 MSc
`29 MSc
` 5 MSc
`
`Page 2 of 13
`
`

`

`May 2020
`
`FAST Funding in partnership with the
`Thistledown Foundation for COVID-19 Science.
`
`2019- 2023
`
`2017-2021
`
`2017-2024
`
`2017-2021
`
`2017 – 2020
`
`2016-2023
`
`2015- 2020
`
`$250,000
`
`
`$5,000,000.00
`
`$250,000.00
`
`$1,720,000.
`
`$4,387,500
`
`$8,600,000
`
`$14,726,30.007
`
`
`$3,702,580.00
`
`$4,990,498.00
`over 5 years
`
`2020-2023 Networks of Centres of Excellence.
`“Biotherapeutics for Cancer Treatment
`(BioCanRx)” Network Scientific Director
`
`Canadian Cancer Society Research Institute
`(CCSRI)-Impact Grant
`Engineering of virally based multiples
`immunotherapeutics. Project Leader
`
`Ontario Institute for Cancer Research (OICR),
`Translational Research Initiative;
`Advancing Immunotherapy Strategies in Ontario.
`Project Leader
`
`Terry Fox Research Institute, New Frontiers
`Program Project Grant (PPG); Canadian
`Oncolytic Virus Consortium (COVCo); Project
`Leader
`
`Ontario Institute for Cancer Research (OICR),
`Translational Research Initiative; Advancing
`Immunotherapy Strategies in Ontario.
`Project Leader(s): John Bell and Marcus Butler;
`
`Canada Foundation for Innovation CFI,
`Innovation fund 2017. Infrastructure to Support
`the discovery and Development of Innovative
`Viroceuticals.
`
`CIHR Foundation Scheme: 2015 2nd Live Pilot:
`“Investigating Virus-Host Interactions to design
`Viral Anti Cancer Therapeutics”.
`
`Prostate Cancer Canada, Movember Team Grant
`Development of a targeted oncolytic virus vaccine
`for the treatment of metastatic prostate cancer. Grant
`number: T2015-01
`
`
`
`PUBLICATIONS 2014-2021 (lifetime total 262; H-index 80 )
`
`(1) Shawn T Beug, Vera A Tang, Eric C LaCasse, Herman H Cheung, Caroline E Beauregard, Jan Brun, Jeffrey P
`Nuyens, Nathalie Earl, Martine St-Jean, Janelle Holbrook, Himika Dastidar, Douglas J Mahoney, Carolina
`Ilkow, Fabrice Le Boeuf, John C Bell & Robert G Korneluk. Smac mimetics and innate immune stimuli
`synergize to promote tumor death. Nat Biotechnol. 2014 Feb;32(2):182-90.
`
`Page 3 of 13
`
`

`

`(2) Wang H, Xu X, Fassett J, Kwak D, Liu X, Hu X, Falls TJ, Bell JC, Li H, Bitterman P, Bache RJ, Chen Y..
`Double-Stranded RNA–Dependent Protein Kinase Deficiency Protects the Heart From Systolic Overload-
`Induced Congestive Heart Failure. Circulation. 2014 Apr 1;129(13):1397-406.
`(3) C. Ilkow, S. Swift, J. Bell, JS. Diallo. From Scourge to Cure: Tumour-Selective Viral Pathogenesis as a New
`Strategy against Cancer. PLoS Pathog. 2014 Jan;10(1):e1003836.
`(4) YU-PING LIU, Jiahu Wang, Victoria Avanzato, Jamie Bakkum-Gamez, Stephen Russell, John Bell, Kah-
`Whye Peng. Oncolytic Vaccinia Virotherapy for Endometrial Cancer. Gynecol Oncol. 2014 Mar;132(3):722-9.
`(5) John Bell and Grant McFadden. Viruses for Tumor Therapy. Cell Host Microbe. 2014 Mar 12;15(3):260-
`265.
`(6) Zhang J, Tai LH, Ilkow CS, Alkayyal AA, Ananth AA, de Souza CT, Wang J, Sahi S, Ly L, Lefebvre C, Falls
`TJ, Stephenson KB, Mahmoud AB, Makrigiannis AP, Lichty BD, Bell JC, Stojdl DF, Auer RC. Maraba MG1
`virus enhances natural killer cell function via conventional dendritic cells to reduce postoperative metastatic
`disease. Mol Ther. 2014 Jul;22(7):1320-32.
`(7) Muik A, Stubbert LJ, Jahedi RZ, Geiß Y, Kimpel J, Dold C, Tober R, Volk A, Klein S, Dietrich U, Yadollahi B,
`Falls T, Miletic H, Stojdl D, Bell JC, von Laer D. Re-engineering vesicular stomatitis virus to abrogate
`neurotoxicity, circumvent humoral immunity and enhance oncolytic potency. Cancer Res. 2014 Jul
`1;74(13):3567-78.
`(8) Cronin M, Le Boeuf F, Murphy C, Roy DG, Falls T, Bell JC, Tangney M. Bacterial-Mediated Knockdown of
`Tumor Resistance to an Oncolytic Virus Enhances Therapy. Mol Ther. 2014 Jun;22(6):1188-97.
`(9) Darija Muharemagic, Anna Zamay, Shahrokh M. Ghobadloo, Laura Evgin, Anna Savitskaya, John Bell,
`Maxim V. Berezovski. "Aptamer-Facilitated Protection of Oncolytic Virus from Neutralizing Antibodies. Mol
`Ther Nucleic Acids. 2014 Jun 3;3:e167
`(10) Bell J. Oncolytic viruses: immune or cytolytic therapy? Mol Ther. 2014 Jul;22(7):1231-2.
`(11) Bell JC. Taming measles virus to create an effective cancer therapeutic. Mayo Clin Proc. 2014 Jul;89(7):863-
`5.
`(12) Brian D. Lichty, Caroline J. Breitbach, David F. Stojdl, & John C. Bell. Going viral with cancer
`immunotherapy. Nature Reviews Cancer. 2014 Aug;14(8):559-67.
`(13) Baldwin RM, Haghandish N, Daneshmand M, Amin S, Paris G, Falls TJ, Bell JC, Islam S, Côté J.Protein
`arginine methyltransferase 7 promotes breast cancer cell invasion through the induction of MMP9 expression.
`Oncotarget. 2014 Dec 26.
`(14) Zeh HJ, Downs-Canner S, McCart JA, Guo ZS, Rao UN, Ramalingam L, Thorne SH, Jones HL, Kalinski P,
`Wieckowski E, O'Malley ME, Daneshmand M, Hu K, Bell JC, Hwang TH, Moon A, Breitbach CJ, Kirn DH,
`Bartlett DL. . First-in-man Study of Western Reserve Strain Oncolytic Vaccinia Virus: Safety, Systemic
`Spread, and Antitumor Activity. Mol Ther. 2015 Jan;23(1):202-14.
`(15) Janne Ruotsalainen, Minna Kaikkonen, Minna Niittykoski, Miika Martikainen, Chantal Lemay, Julie Cox,
`Naomi De Silva, Agnieszka Kus, Theresa Falls, Jean-Simon Diallo, Fabrice Le Boeuf, John Bell, Seppo Yla-
`Herttuala, Ari Hinkkanen, and Markus Vähä-Koskela. Clonal Variation in Interferon Response Determines the
`Outcome of Oncolytic Virotherapy in Mouse CT26 Colon Carcinoma Model. Gene Ther. 2015 Jan;22(1):65-
`75.
`(16) Breitbach CJ, Bell JC, Hwang TH, Kirn DH, Burke J. THE emerging therapeutic potential of the oncolytic
`immunotherapeutic Pexa Vec JX594. January 2015 Volume 2015:4 Pages 25-31.
`
`Page 4 of 13
`
`

`

`(17) Rozanne Arulanandam, Cory Batenchuk, Oliver Varette, Chadi Zakaria, Nicole E. Forbes, Colin Davis, Ramya
`Krishnan, Vanessa Garcia, Raunak Karmacharya, Julie Cox, Anisha Sinha, Andrew Babawy, Katherine Waite,
`Erica Weinstein, Theresa Falls, Andrew Chen, Jeff Hamill, Naomi Da Silva, David P. Conrad, Harold Atkins,
`Kenneth Garson, Carolina Ilkow, Mads Kaern, Barbara Vanderhyden, Nahum Sonenberg, Tommy Alain,
`Fabrice Le Boeuf , *John C. Bell, *Jean-Simon Diallo. Microtubule Destabilizers Disrupt Interferon Production
`and Sensitize to Rhabdovirus Bystander Killing. Nat Commun. 2015 Mar 30;6:6410. IF 10.742
`(18) Cripe TP, Ngo MC, Geller JI, Louis CU, Currier MA, Racadio JM, Towbin AJ, Rooney CM, Pelusio A, Moon
`A, Hwang TH, Burke JM, Bell JC, Kirn DH, Breitbach CJ. Phase 1 Study of Intratumoral Pexa-Vec (JX-594),
`an Oncolytic and Immunotherapeutic Vaccinia Virus, in Pediatric Cancer Patients. Mol Ther. 2015
`Mar;23(3):602-8.
`(19) Carolina S. Ilkow, Monique Marguerie, Cory Batenchuk, Justin Mayer, Daniela Ben Neriah, Sophie Cousineau,
`Theresa Falls, Victoria Jennings, Meaghan Boileau, David Bellamy, Donald Bastin1, Christiano Tanese de
`Souza, Almohanad Alkayyal, Jiging Zhang, Fabrice LeBoeuf, Rozanne Arulanandam, Lawton Stubbert, Padma
`Sampath, Steve Thorne, Piriya Paramanthan, Avijit Chatterjee, Robert M. Strieter, Marie Burdick, Christina
`Addison David F. Stojdl, Harold L. Atkins, Rebecca Auer, , Jean-Simon Diallo, Brian Lichty, and John C. Bell.
`Reciprocal cellular cross-talk within the tumor microenvironment promotes oncolytic virus activity. Nat Med.
`2015 May;21(5):530-6. IF 28.054
`(20) Laura Evgin, Sergio A. Acuna, Christiano Tanese de Souza, Monique Marguerie, Chantal G. Lemay, Carolina
`S. Ilkow, Scott C. Findlay, Theresa Falls, Kelley A. Parato, David Hanwell, Alyssa Goldstein, Roberto Lopez,
`Sandra Lafrance, Caroline J. Breitbach, David Kirn, Harold Atkins, Rebecca C. Auer, Joshua M. Thurman,
`Gregory L. Stahl, John D. Lambris, John C. Bell1,* J. Andrea McCart. Complement inhibition prevents
`oncolytic vaccinia virus neutralization in immune humans and cynomolgus macaques. Mol Ther. 2015
`Jun;23(6):1066-76 . IF 6.425
`(21) Rozanne Arulanandam, Cory Batenchuk, Fernando A. Angarita, Kathryn Ottolino-Perry, Sophie Cousineau,
`Amelia Mottashed, Emma Burgess, Theresa J. Falls, Naomi De Silva, Jovian Tsang, Grant A. Howe, Marie-
`Claude Bourgeois-Daigneault, David P. Conrad, Manijeh Daneshmand, Caroline J. Breitbach, David H. Kirn,
`Leda Raptis, Subash Sad, Harold Atkins, Michael S. Huh, Jean-Simon Diallo, Brian Lichty, Carolina S. Ilkow,
`Fabrice Le Boeuf, Christina L. Addison, J. Andrea Mc Cart and John C. Bell. VEGF-mediated induction of
`PRD1-BF1/Blimp1 expression sensitizes tumour vasculature to oncolytic virus infection. Cancer Cell. 2015
`Aug 10;28(2):210-24.
`(22) Breitbach CJ, Parato K, Burke J, Hwang TH, Bell JC, Kirn DH. Pexa-Vec double agent engineered vaccinia:
`oncolytic and active immunotherapeutic.Curr Opin Virol. 2015 Aug;13:49-54.
`(23) Bell, John, McFadden G. Editorial overview: Oncolytic Viruses - Replicating Virus Therapeutics for the
`Treatment of Cancer. Curr Opin Virol. 2015 Aug;13:viii-ix.
`(24) Trevor Shepherd, Jessica Tong, Yudith Valdes, John Barrett, John Bell, David Stojdl, J McCart, Grant
`McFadden, and Gabriel DiMattia. Evidence for differential viral oncolytic efficacy in an in vitro model of
`epithelial ovarian cancer metastasis. Mol Ther Oncolytics. 2015 Sep 23;2:15013.
`(25) Roy DG, Power AT, Bourgeois-Daigneault MC, Falls T, Ferreira L, Stern A, Tanese de Souza C, McCart JA,
`Stojdl DF, Lichty BD, Harold L. Atkins, Auer RC, Bell JC, Le Boeuf F.. Programmable insect cell carriers for
`systemic delivery of integrated cancer biotherapy. Journal of Controlled Release. October 16, 2015.
`(26) Ard R, Mulatz K, Pomoransky JL, Parks RJ, Trinkle-Mulcahy L, Bell JC, Gee SH. Regulation of
`Macropinocytosis by Diacylglycerol Kinase ζ. PLoS One. 2015 Dec 23;10(12).
`(27) Paul Beaudry, Juan Corredor, Nicole Redding, Karen Bloté, Stephen Robbins, Donna L. Senger, and John Bell.
`N-Myc expression enhances the oncolytic effects of vesicular stomatitis virus in human neuroblastoma cells.
`Molecular Therapy – Oncolytics (Accepted).
`
`Page 5 of 13
`
`

`

`(28) Bourgeois-Daigneault MC, Roy DG, Falls T, Twumasi-Boateng K, St-Germain LE, Marguerie M, Garcia V,
`Selman M, Jennings VA, Pettigrew J, Amos S, Diallo JS, Nelson B, Bell JC. Oncolytic vesicular stomatitis
`virus expressing interferon-γ has enhanced therapeutic activity. Mol Ther Oncolytics. 2016 Feb 17;3:16001.
`(29) Wong CM, Poulin KL, Tong G, Christou C, Kennedy MA, Fall T, Bell JC, Parks RJ. Adenovirus-Mediated
`Expression of the p14 Fusion-Associated Small Transmembrane Protein Promotes Cancer Cell Fusion and
`Apoptosis In Vitro but Does Not Provide Therapeutic Efficacy in a Xenograft Mouse Model of Cancer. PLoS
`One. 2016 Mar 17;11(3):e0151516.
`(30) Falls T, Roy DG, Bell JC, Bourgeois-Daigneault MC. Murine Tumor Models for Oncolytic Rhabdo-
`Virotherapy. ILAR J. 2016 Mar 31;57(1):73-85.
`(31) Ungerechts G, Bossow S, Leuchs B, Holm PS, Rommelaere J, Coffey M, Coffin R, Bell J, Nettelbeck DM.
`Moving oncolytic viruses into the clinic: clinical-grade production, purification, and characterization of diverse
`oncolytic viruses. Mol Ther Methods Clin Dev. 2016 Apr 6;3:16018.
`(32) Ananth AA, Tai LH, Lansdell C, Alkayyal AA, Baxter KE, Angka L, Zhang J, Tanese de Souza C, Stephenson
`KB, Parato K, Bramson JL, Bell JC, Lichty BD, Auer RC. Surgical Stress Abrogates Pre-existing Protective T
`Cell Mediated Anti-tumor Immunity Leading to Postoperative Cancer Recurrence. PLoS One. 2016 May
`19;11(5):e0155947.
`(33) Mark H. Dornan, Ramya Krishnan, Andrew M. Macklin, Mohammed Selman, Nader El Sayes, Colin Davis,
`Andrew Chen, Kerkeslin Keillor, Penny Le, Christina Moi, Paula Ou, Christophe Pardin, Fabrice Le Boeuf,
`John C. Bell, Jeffrey C. Smith,* Jean-Simon Diallo,* Christopher N. Boddy * First-in-class small molecule
`potentiators of cancer virotherapy. Nature Sci Rep. 2016 May 26;6:26786. Marie-Claude Bourgeois-
`Daigneault; Lauren Elizabeth St-Germain; Dominic Guy Roy; Adrian Pelin; Amelia Sadie Aitken; Rozanne
`Arulanandam; Theresa Falls; Vanessa Garcia; Jean-Simon Diallo; John Cameron Bell. Combination of
`Paclitaxel and MG1 oncolytic virus as a successful strategy for breast cancer treatment. Breast Cancer Res.
`2016 Aug 8;18(1):83.
`(34) Breitbach CJ, Lichty BD, Bell JC. Oncolytic Viruses: Therapeutics With an Identity Crisis. EBioMedicine.
`2016 Jul;9:31-6.
`(35) Keller BA, Bell JC.(2016). Oncolytic viruses-immunotherapeutics on the rise. J Mol Med (Berl). 2016
`Sep;94(9):979-991.
`(36) Tang VA, Renner TM, Varette O, Le Boeuf F, Wang J, Diallo JS, Bell JC, Langlois MA. Single-particle
`characterization of oncolytic vaccinia virus by flow virometry. Vaccine. 2016 Sep 30;34(42):5082-9.
`(37) Evgin L, Ilkow CS, Bourgeois-Daigneault MC, de Souza CT, Stubbert L, Huh MS, Jennings VA, Marguerie M,
`Acuna SA, Keller BA, Lefebvre C, Falls T, Le Boeuf F, Auer RA, Lambris JD, McCart JA, Stojdl DF, Bell JC.
`Complement inhibition enables tumor delivery of LCMV glycoprotein pseudotyped viruses in the presence of
`antiviral antibodies. Mol Ther Oncolytics. 2016 Nov 16;3:16027
`(38) Rūta Veinalde, Christian Grossardt, Laura hartman, Marie-Claude Bourgeois-Daigneault, John C. Bell, Dirk
`Jäger, Christof von Kalle, Guy Ungerecths, & Chrisitne E. Engeland. Oncolytic measles virus encoding
`interleukin-12 mediates potent anti-tumor effects through T cell activation. Oncoimmunology. 2017 Jan
`31;6(4).
`(39) Derek J. Jonker, Sebastien J. Hotte, Albiruni Ryan Abdul Razak, Daniel John Renouf, Brian Lichty, John C.
`Bell, Jean Powers, Caroline J Breitbach, David F Stojdl, Kyle B Stephenson, Jonathan L Bramson, Jeff
`Hummel, Chantal G Lemay, Jean-Claude Cutz, Julie Wells, Robin Eady, Xiaoqun Sun, Dongsheng Tu, Janet
`Dancey. Phase I study of oncolytic virus (OV) MG1 maraba/MAGE-A3 (MG1MA3), with and without
`transgenic MAGE-A3 adenovirus vaccine (AdMA3) in incurable advanced/metastatic MAGE-A3-expressing
`solid tumours: CCTG IND.214.
`
`Page 6 of 13
`
`

`

`(40) Lemay CG, Keller BA, Edge RE, Abei M, Bell JC. Oncolytic Viruses: The Best is Yet to Come. Curr Cancer
`Drug Targets. 2017 Feb 6.
`(41) Wang J, Arulanandam R, Wassenaar R, Falls T, Petryk J, Paget J, Garson K, Cemeus C, Vanderhyden B, Wells
`G, Bell J, Le Boeuf F. Enhancing expression of functional human sodium iodide symporter and somatostatin
`receptor in recombinant oncolytic vaccinia virus for in vivo imaging of tumors. J Nucl Med. 2017 Feb
`15;58(2):221-227.
`(42) Alkayyal AA, Tai LH, Kennedy MA, de Souza CT, Zhang J, Lefebvre C, Sahi S, Ananth AA, Mahmoud AB,
`Makrigiannis AP, Cron GO, Macdonald B, Marginean EC, Stojdl DF, Bell JC, Auer RC. NK-Cell Recruitment
`Is Necessary for Eradication of Peritoneal Carcinomatosis with an IL12-Expressing Maraba Virus Cellular
`Vaccine. Cancer Immunol Res. 2017 Mar;5(3):211-221.
`(43) Le Boeuf F, Selman M, Hee Son H, Bergeron A, Chen A, Tsang J, Butterwick D, Arulanandam R, Forbes NE,
`Tzelepis F, Bell JC, Werier J, Abdelbary H, Diallo JS. Oncolytic Maraba virus MG1 as a treatment for
`Sarcoma. Int J Cancer. 2017 Sep 21;141(6):1257-1264.
`(44) Morettin A, Paris G, Bouzid Y, Baldwin RM, Falls TJ, Bell JC, Côté J. Tudor Domain Containing Protein 3
`Promotes Tumorigenesis and Invasive Capacity of Breast Cancer Cells. Sci Rep 2017 Jul 11;7(1):5153.
`(45) John C. Bell, and Carolina S. Ilkow. A Viro-Immunotherapy Triple Play for the Treatment of Glioblastoma.
`Cancer Cell Volume 32, Issue 2, August 14, 2017:133-134.
`(46) Le Boeuf F, Gebremeskel S, McMullen N, He H, Greenshields AL, Hoskin DW, Bell JC, Johnston B, Pan C,
`Duncan R. Reovirus FAST Protein Enhances Vesicular Stomatitis Virus Oncolytic Virotherapy in Primary and
`Metastatic Tumor Models. Mol Ther Oncolytics. 2017 Aug 4;6:80-89
`(47) Kevin W. Ng, Erin a. Marshall, John C. Bell, Wan L. Lam. cGAS-STING and Cancer: Dichotomous Roles in
`Tumor Immunity and Development. Trends in Immunology, 2017 Aug 19. pii: S1471-4906(17)30151-5.
`(48) Jessica G. Tong, Yudith Ramos Valdes, Milani Sivapragasam, John W. Barrett, John C. Bell, David Stojdl,
`Gabriel E. DiMattia, Trevor Shepherd. Spatial and temporal epithelial ovarian cancer cell heterogeneity impacts
`Maraba virus oncolytic potential. BMC Cancer. 2017 Aug 30;17(1):594.
`(49) Selman M, Rousso C, Bergeron A, Son HH, Krishnan R, El-Sayes NA, Varette O, Chen A, Le Boeuf F,
`Tzelepis F, Bell JC, Crans DC, Diallo JS. Multi-modal Potentiation of Oncolytic Virotherapy by Vanadium
`Compounds. Mol Ther. 2017 Oct 24. pii: S1525-0016(17)30530-0.
`(50) Guo ZS, Liu Z, Sathaiah M, Wang J, Ravindranathan R, Kim E, Huang S, Kenniston TW, Bell JC, Zeh HJ 3rd,
`Butterfield LH, Gambotto A, Bartlett DL. Rapid Generation of Multiple Loci-Engineered Marker-free Poxvirus
`and Characterization of a Clinical-Grade Oncolytic Vaccinia Virus. Mol Ther Methods Clin Dev. 2017 Sep
`30;7:112-122.
`(51) M.J. Atherton, L. Evgin, B.A. Keller, M.M. Shenouda, K.B. Stephenson, R.G. Vile, J.C. Bell, D.H. Evans &
`B.D. Lichty. Infectious Optimism Following the 10th International Oncolytic Virus Meeting. Molecular
`Therapy: Oncolytics. December 2017 Vol 7:12-16.
`(52) Kevin W. Ng, Erin a. Marshall, John C. Bell, Wan L. Lam. cGAS-STING and Cancer: Dichotomous Roles in
`Tumor Immunity and Development. Trends in Immunology 2018 Jan;39(1):44-54.
`(53) Marie-Claude Bourgeois-Daigneault, Dominic Guy Roy, Amelia Sadie Aitken, Nader El Sayes, Nikolas Tim
`Martin, Oliver Varette, Theresa Falls, Lauren Elizabeth St-Germain, Adrian Pelin, Brian Dennis Lichty, David
`Francis Stojdl, Guy Ungerechts, Jean-Simon Diallo, John Cameron Bell. Neo-Adjuvant Oncolytic
`Virotherapy Before Surgery Sensitizes Triple-Negative Breast Cancer to Immune Checkpoint Therapy. Science
`Translational Medicine. 03 Jan 2018:Vol. 10, Issue 422.
`
`Page 7 of 13
`
`

`

`(54) Selman M, Ou P, Rousso C, Bergeron A, Krishnan R, Pikor L, Chen A, Keller BA, Ilkow C, Bell JC, Diallo JS.
`Dimethyl Fumarate potentiates oncolytic virotherapy through NF-kB inhibition. Sci Transl Med. 2018 Jan
`24;10(425).
`(55) Pelin A, Wang J, Bell J, Le Boeuf F. The importance of imaging strategies for pre-clinical and clinical in vivo
`distribution of oncolytic viruses. Oncolytic Virother. 2018 Mar 28;7:25-35.
`(56) Matthew J. Atherton, Kyle B. Stephenson, Fanny Tzelepis, David Bakhshinyan, Jake K. Nikota, Hwan Hee
`Son, Anna Jirovec, Charles Lefebvre, Anna Dvorkin-Gheva, Ali A. Ashkar, Yonghong Wan, David F. Stojdl,
`Eric C. Belanger, Rodney H. Breau, John C. Bell, Fred Saad, Sheila K. Singh, Jean-Simone Diallo & Brian D.
`Lichty. Transforming the prostatic tumor microenvironment with oncolytic virotherapy. OncoImmunology.
`2018 Mar 27;7(7).
`(57) Aitken AS, Roy DG, Martin NT, Sad S, Bell JC, Bourgeois-Daigneault MC. Brief Communication; A
`Heterologous Oncolytic Bacteria-Virus Prime-Boost Approach for Anticancer Vaccination in Mice. J
`Immunother.. 2018 Apr;41(3):125-129.
`(58) Stephanie Michaud, Louise Binder, John C. Bell, Kathy Brodeur-Robb, Patrick Sullivan, Marcus O. Butler;
`From Muridae to Homo: Patient-researcher engagement in the research translation continuum. 2018 ASCO
`Annual Meeting (June 1-5, 2018), Chicago, USA.
`(59) Donald Bastin, Amelia S. Aitken, Adrian Pelin, Larissa A. Pikor, Mathieu J.F. Crupi, Michael S. Huh, Marie –
`Claude Bourgeois-Daigneault, John C. Bell, Carolina S. Ilkow. Enhanced susceptibility of cancer cells to
`oncolytic rhabdo-virotherapy by expression of Nodamura virus protein B2 as a suppressor of RNA interference.
`Journal for Immunotherapy of Cancer 2018 Jun 19;6(1):62.
`(60) Carole Achard, Abera Surendran, Marie-Eve Wedge, Guy Ungerechts, John C. Bell and Carolina S. Ilkow.
`Lighting a fire in tumor microenvironments using oncolytic immunotherapy. EBioMedicine 2018 May;31:17-
`24.
`
`
`(61) Kwame Twumasi-Boateng, Jessica L. Pettigrew, Y.Y. Eunice Kwok, John C. Bell, and Brad H. Nelson (2018)
`Oncolytic viruses as engineering platforms for combination immunotherapy. Nature Reviews Cancer 2018
`Jul;18(8):526.
`(62) Nikolas T Martin and John C Bell (2018) Oncolytic Virus Combination Therapy: Killing one bird with two
`stones. Molecular Therapy 2018 Jun 6;26(6):1414-1422.
`(63) Ashley T. Chen, Briana L.R. Samson, Mathieu J.F. Crupi, John C. Bell (2018) Oncolytic viruses: Cytolytic
`Agents, Replicating Immunotherapeutics or Both? Future Virology, June 12, 2018 Vol 13, Issue 7, 445-448.
`(64) Rosales Gerpe MC, van Vloten JP, Santry LA, de Jong J, Mould RC, Pelin A, Bell JC, Bridle BW, Wootton
`SK. Use of Precision-Cut Lung Slices as an Ex Vivo Tool for Evaluating Viruses and Viral Vectors for Gene
`and Oncolytic Therapy. Mol Ther Methods Clin Dev. 2018 Aug 4;10:245-256.
`(65) Zakaria C, Sean P, Hoang HD, Leroux LP, Watson M, Workenhe ST, Hearnden J, Pearl D, Truong VT,
`Robichaud N, Yanagiya A, Tahmasebi S, Jafarnejad SM, Jia JJ, Pelin A, Diallo JS, Le Boeuf F, Bell JC,
`Mossman KL, Graber TE, Jaramillo M, Sonenberg N, Alain T. Active-site mTOR inhibitors augment HSV1-
`dICP0 infection in cancer cells via dysregulated eIF4E/4E-BP axis. PLoS Pathog. 2018 Aug 23;14(8).
`(66) G Pol J, Lévesque S, Workenhe ST, Gujar S, Le Boeuf F, R Clements D, Fahrner JE, Fend L, C Bell J, L
`Mossman K, Fucikova J, Spisek R, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Oncolytic viro-
`immunotherapy of hematologic and solid tumors. Oncoimmunology. 2018 Aug 27;7(12).
`(67) Pol JG, Acuna SA, Yadollahi B, Tang N, Stephenson KB, Atherton MJ, Hanwell D, El-Warrak A, Goldstein A,
`Moloo B, Turner PV, Lopez R, LaFrance S, Evelegh C, Denisova G, Parsons R, Millar J, Stoll G, Martin CG,
`
`Page 8 of 13
`
`

`

`Pomoransky J, Breitbach CJ, Bramson JL, Bell JC, Wan Y, Stojdl DF, Lichty BD, McCart JA. Preclinical
`evaluation of a MAGE-A3 vaccination utilizing the oncolytic Maraba virus currently in first-in-human trials.
`Oncoimmunology. 2018 Sep 19;8(1).
`(68) Hsu J, Hodgins JJ, Marathe M, Nicolai CJ, Bourgeois-Daigneault MC, Trevino TN, Azimi CS, Scheer AK,
`Randolph HE, Thompson TW, Zhang L, Iannello A, Mathur N, Jardine KE, Kirn GA, Bell JC, McBurney MW,
`Raulet DH, Ardolino M. Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade.J Clin
`Invest. 2018 Oct 1;128(10):4654-4668.
`(69) Pol JG, Atherton MJ, Bridle BW, Stephenson KB, Le Boeuf F, Hummel JL, Martin CG, Pomoransky J,
`Breitbach CJ, Diallo JS, Stojdl DF, Bell JC, Wan Y, Lichty BD. Development and applications of oncolytic
`Maraba virus vaccines. Oncolytic Virother. 2018 Nov 26;7:117-128.
`(70) Walsh SR, Bastin D, Chen L, Nguyen A, Storbeck CJ, Lefebvre C, Stojdl D, Bramson JL, Bell JC, Wan Y.
`Type I IFN blockade uncouples immunotherapy-induced antitumor immunity and autoimmune toxicity. J Clin
`Invest. 2019 129(2):518-530.
`(71) Gujar S, Bell J, Diallo JS. SnapShot: Cancer Immunotherapy with Oncolytic Viruses. Cell. 2019
`21;176(5):1240-1240.
`(72) Martin NT, Roy DG, Workenhe ST, van den Wollenberg DJM, Hoeben RC, Mossman KL, Bell JC, Bourgeois-
`Daigneault MC. Pre-surgical neoadjuvant oncolytic virotherapy confers protection against rechallenge in a
`murine model of breast cancer. Sci Rep. 2019 12;9(1):1865
`(73) Del Papa J, Petryk J, Bell JC, Parks RJ. An Oncolytic Adenovirus Vector Expressing p14 FAST Protein
`Induces Widespread Syncytium Formation and Reduces Tumor Growth Rate In Vivo. Mol Ther Oncolytics.
`2019 15;14:107-120.
`(74) Crupi, MJF, Bell, JC, Singaravelu R. Concise Review: Targeting cancer stem cells and their supporting niche
`using oncolytic viruses. Stem Cells 2019 37(6):716-723.
`(75) Pelin A, Foloppe J, Petryk J, Singaravelu R, Hussein M, Gossart F, Jennings VA, Stubbert LJ, Foster M,
`Storbeck C, Postigo A, Scut E, Laight B, Way M, Erbs P, Le Boeuf F, Bell JC. Deletion of Apoptosis Inhibitor
`F1L in Vaccinia Virus Increases Safety and Oncolysis for Cancer Therapy.Mol Ther Oncolytics. 2019
`3;14:246-252.
`(76) Engeland CE, Bell JC. Introduction to Oncolytic Virotherapy. Methods Mol Biol. 2020;2058:1-6.
`(77) Leber MF, Hoyler B, Prien S, Neault S, Engeland CE, Förster JM, Bossow S, Springfeld C, von Kalle C, Jäger
`D, Bell JC, Ungerechts G. Sequencing of serially passaged measles virus affirms its genomic stability and
`reveals a nonrandom distribution of consensus mutations. J Gen Virol. 2020 101(4):399-409.
`(78) Aalipour A, Le Boeuf F, Tang M, Murty S, Simonetta F, Lozano AX, Shaffer TM, Bell JC, Gambhir SS. Viral
`Delivery of CAR Targets to Solid Tumors Enables Effective Cell Therapy. Mol Ther Oncolytics. 2020
`7;17:232-240.
`(79) Pelin A, Boulton S, Tamming LA, Bell JC, Singaravelu R. Engineering vaccinia virus as an immunotherapeutic
`battleship to overcome tumor heterogeneity. Expert Opin Biol Ther. 2020 Sep;20(9):1083-1097.
`(80) Bell JC. Check and Ckeckmate: Battling Cancer with Multiplex Immunotherapy. Mol Ther. 2020
`6;28(5):1236-1237.
`(81) Roy DG, Bell JC, Bourgeois-Daigneault MC. Magnetic targeting of oncolytic VSV-based therapies improves
`infection of tumor cells in the presence of virus-specific neutralizing antibodies in vitro. Biochem Biophys Res
`Commun . 2020 Jun 4;526(3):641-646.
`
`Page 9 of 13
`
`

`

`(82) Al-Zahrani KN, Abou-Hamad J, Cook DP, Pryce BR, Hodgins JJ, Labrèche C, Robineau-Charette P, de Souza
`CT, Bell JC, Auer RC, Ardolino M, Vanderhyden BC, Sabourin LA. Loss of the Ste20-like kinase induces a
`basal/stem-like phenotype in HER2-positive breast cancers. Oncogene. 2020 Jun;39(23):4592-4602.
`(83) Taha Azad, Reza Rezaei, Abera Surendran, Ragunath Singaravelu, Stephen Boulton, Jaahnavi Dave, John C.
`Bell, Carolina Ilkow. Hippo Signaling Pathway as a Central Mediator of Receptors Tyrosine Kinases (RTKs) in
`Tumorigenesis. 24 July 2020 12(8), 2042 Cancers.
`(84) Mathias F. Leber , Serge Neault, Elise Jirovec , Russell Barkley, Aida Said, John C. Bell, Guy Ungerechts.
`Engineering and combining oncolytic measles virus for cancer therapy. Elsevier, Cytokine Growth Factor
`Rev. 2020 56:39-48.
`(85) Azad T, Singaravelu R, Crupi MJF, Jamieson T, Dave J, Brown EEF, Rezaei R, Taha Z, Boulton S, Martin NT,
`Surendran A, Poutou J, Ghahremani M, Nouri K, Whelan JT, Duong J, Tucker S, Diallo JS, Bell JC, Ilkow CS.
`Implications for SARS-CoV-2 Vaccine Design: Fusion of Spike Glycoprotein Transmembrane Domain to
`Receptor-Binding Domain Induces Trimerization. Membranes 2020 Aug 30;10(9):215.
`(86) Azad T, Singaravelu R, Taha Z, Jamieson TR, Boulton S, Crupi MJF, Martin NT, Brown EEF, Poutou J,
`Ghahremani M, Pelin A, Nouri K, Rezaei R, Marshall CB, Enomoto M, Arulanandam R, Alluqmani N, Samson
`R, Gingras AC, Cameron DW, Greer PA, Ilkow CS, Diallo JS, Bell JC. Nanoluciferase complementation-based
`bioreporter reveals the importance of N-linked glycosylation of SARS-CoV-2 S for viral entry. Mol Ther. 2021
`Jun 2;29(6):1984-2000
`(87) Azad T, Singaravelu R, Brown EEF, Taha Z, Rezaei R, Arulanandam R, Boulton S, Diallo JS, Ilkow CS, Bell
`JC. SARS-CoV-2 S1 NanoBiT: A nanoluciferase complementation-based biosensor to rapidly probe SARS-
`CoV-2 receptor recognition. Biosens Bioelectron. 2021 May 15;180:113122.
`(88) Keller BA, Laight BJ, Varette O, Broom A, Wedge MÈ, McSweeney B, Cemeus C, Petryk J, Lo B, Burns B,
`Nessim C, Ong M, Chica RA, Atkins HL, Diallo JS, Ilkow CS, Bell JC. Personalized oncology and
`BRAFK601N melanoma: model development, drug discovery, and clinical correlation. Cancer Res Clin Oncol.
`2021 May;147(5):1365-1378.
`(89) Singh HM, Leber MF, Bossow S, Engeland CE, Dessila J, Grossardt C, Zaoui K, Bell JC, Jäger D, von Kalle C,
`Ungerechts G. MicroRNA-sensitive oncolytic measles virus for chemovirotherapy of pancreatic cancer. Mol
`Ther Oncolytics. 2021 May 5;21:340-355
`(90) Brown EEF, Rezaei R, Jamieson TR, Dave J, Martin NT, Singaravelu R, Crupi MJF, Boulton S, Tucker S,
`Duong J, Poutou J, Pelin A, Yasavoli-Sharahi H, Taha Z, Arulanandam R, Surendran A, Ghahremani M, Austin
`B, Matar C, Diallo JS, Bell JC, Ilkow CS, Azad T Characterization of Critical Determinants of ACE2-SARS
`CoV-2 RBD Interaction. Int J Mol Sci. 2021 Feb 25;22(5):2268
`(91) Roy D. G., Geoffroy K., Marguerie M., Khan S. T., Martin N. T., Kmiecik J., Bobbala D., Aitken A.
`S., C. T. de Souza, Stephenson K. B., Lichty B. D., Auer R. C., Stojdl D. F., Bell J. C. and Bourgeois-
`Daigneault M.-C. Adjuvant oncolytic virotherapy for personalized anti-cancer vaccination. Nature
`Communications 2021 May 11;12(1):2626.
`(92) Afsaneh Sadremomtaz, Zayana M. Al-Dahmani, Angel J. Ruiz-Moreno, Alessandra Monti, Chao
`Wang, Taha Azad, John C. Bell, Nunzianna Doti, Marco A. Velasco-Velázquez, Debora de Jong,
`Jørgen de Jonge, Jolanda Smit, Alexander Dömling, Harry van Goor*, and Matthew R. Groves*.
`Synthetic Peptides That Antagonize the Angiotensin-Converting Enzyme-2 (ACE-2) Interaction with
`SARS-CoV-2 Receptor Binding Spike Protein. J Med. 2021 Jul 30;acs.jmedchem.1c00477.
`(93) Taha Azad, Helena J. Janse van Rensburg, Jessica Morgan, Reza Rezaei, Mathieu J. F. Crupi, Rui
`Chen, Mina Ghahremani, Monire Jamalkhah, Nicole Forbes, Carolina Ilkow and John C. Bell*.
`
`Page 10 of 13
`
`

`

`Luciferase-Based Biosensors in the Era of the COVID-19 Pandemic. ACS Nanosci. Au Publica